New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 15, 2014
07:55 EDTVTLVital Therapies price target raised to $35 from $20 at Canaccord
Canaccord raised its price target on Vital Therapies to $35 from $20 based on the probability of the success of its Alcohol Induced Liver Disease drug and its substantial market opportunity. Canaccord maintains its Buy rating on Vital Therapies.
News For VTL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
10:11 EDTVTLHigh option volume stocks
High option volume stocks: CMPR TPX WMC YRCW VTL HBI RNG MXWL GLF EXPE
July 30, 2015
16:14 EDTVTLVital Therapies reports Q2 EPS (63c), consensus (62c)
"As we approach data lock and analysis of VTI-208 results, we are pleased to report we are on schedule to report topline results later this quarter. VTI-208 is the largest liver support system clinical trial ever conducted, was run on three continents and enrolled 203 subjects. Needless to say we are excitedly awaiting these results," said Terry Winters, Ph.D., CEO and Co-Chairman. Cash and cash equivalents at June 30 totaled $71.9M, compared to $102.2M at December 31, 2014. Based on the current business plan, the company believes it has enough cash to fund the company into the third quarter of 2016, although the company's projections will be highly dependent on the topline results of the VTI-208 clinical trial.
July 27, 2015
06:56 EDTVTLVital Therapies to address 'certain misinformation' during Q2 call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use